Skip to main content

ORIGINAL RESEARCH article

Front. Surg.
Sec. Orthopedic Surgery
Volume 11 - 2024 | doi: 10.3389/fsurg.2024.1433265

Enhancing prognosis in multiple myeloma bone disease: insights from a retrospective analysis of surgical interventions

Provisionally accepted
Xiangjun Shi Xiangjun Shi 1Xingchen Yao Xingchen Yao 2Yue Wu Yue Wu 2Boran Du Boran Du 3Xinru Du Xinru Du 4*
  • 1 Beijing Tiantan Hospital, Capital Medical University, Beijing, Beijing Municipality, China
  • 2 Beijing Chaoyang Hospital, Capital Medical University, Beijing, Beijing Municipality, China
  • 3 Shijiazhuang Obstetrics and Gynecology Hospital, Shijiazhuang, Hebei Province, China
  • 4 Beijing Chao-Yang Hospital, Beijing, China

The final, formatted version of the article will be published soon.

    Multiple myeloma (MM) is a hematological malignancy characterized by bone marrow infiltration and osteolytic tumor formation. Despite advancements in the treatment of this disease, MM remains incurable and often leads to complications, such as multiple myeloma bone disease (MMBD). Surgical intervention is frequently necessary to manage symptoms associated with bone disease, including pain and fractures. The present retrospective analysis aimed to evaluate the role of surgery in improving patient prognosis compared with chemotherapy alone. The present study analyzed clinical and laboratory characteristics, as well as survival outcomes, of patients who underwent surgical intervention combined with chemotherapy compared with those who received chemotherapy alone.Although surgical suitability varied among patients, it was found that the overall survival was significantly longer in patients who underwent surgery compared with those who had not undergone surgery throughout the study period. However, larger clinical studies are required to further investigate the effectiveness of surgical interventions compared with chemotherapy in prolonging overall survival.

    Keywords: Multiple Myeloma, prognosis, Surgical, Multiple myeloma bone disease, chemotherapy

    Received: 29 Sep 2024; Accepted: 03 Dec 2024.

    Copyright: © 2024 Shi, Yao, Wu, Du and Du. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Xinru Du, Beijing Chao-Yang Hospital, Beijing, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.